During many past years, Kempler has not been so convinced as he was last Friday:
“We believe that our science is unique, validated, and is capturing the attention of physicians and
researchers for its potential to have a positive impact on the lives of many people suffering from
Parkinsonian diseases which currently have no cure.”
Unfortunately, ATH has not told us much but the Finkelstein paper almost 3.5 years ago and a couple of Stamler's posters. In a way, I trust that they have something unique, but my opinion is only an opinion without specific ATH434 study results Kempler already has, most likely, at last from phase 1.
Kempler's statement was strong
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $20.98M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $14.55K | 3.241M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 62 | 71906262 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 32338803 | 25 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| ATH (ASX) Chart |